Recursion Pharmaceuticals amends Tempus AI data pact and licenses RNA model for oncology

Recursion Pharmaceuticals disclosed in an 8-K dated September 15, 2026 that it had entered into two new agreements with Tempus AI, Inc., tied to what the company described as Tempus's library of multimodal data and Recursion's proprietary foundational RNA sequencing model, known as the TxFM Model¹.

The first is an amendment to the companies' existing Master Agreement, originally dated November 3, 2023. That original deal ran for a five-year term and let Recursion terminate for convenience after the first three years¹, with annual license fees of $22 million in year one, $32 million in year two, and $42 million in each of years three and four, payable up to 100% in Recursion Class A shares at the company's option¹.

Under the amendment, Recursion agreed to stretch the agreement's term from five to six years, give up its right to terminate for convenience, cut the remaining annual fees to $14 million each on the third, fourth and fifth anniversaries (with at least $4 million of each payment in cash and the rest in stock, cash, or a mix), and reduce the total volume of de-identified data records it can access over the term¹.

Separately, on the same date, Recursion signed a new RNA Foundation Model License Agreement granting Tempus rights to the TxFM Model. The license is non-exclusive, non-sublicensable, and non-transferable, covering worldwide use limited to oncology¹, and it covers diagnostic and clinical uses as well as Tempus's own internal research and development¹. This license runs for two years from its effective date.¹

In exchange, Tempus will pay Recursion a non-refundable $12 million fee in two $6 million installments, one at signing and one on the first anniversary¹, and will give Recursion access to a set number of de-identified pathology records with linked clinical data during the license term¹. Full agreement texts are expected to be filed with Recursion's future quarterly report, per the filing.